CXCR4 inhibition alleviates prostatic inflammation and pelvic pain via suppressing Th17 cell differentiation and oxidative stress in EAP mice.

ABSTRACT: Background: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) represents a prevalent urological disorder characterized by urinary symptoms, persistent pelvic or perineal discomfort accompanied by intraprostatic leukocyte infiltration. The C-X-C chemokine receptor type 4 (CXCR4) is critically involved in mediating inflammatory responses. Nevertheless, the specific involvement of CXCR4 in the immunoinflammatory mechanisms underlying CP/CPPS pathogenesis remains poorly characterized. Methods: The therapeutic efficacy of AMD3100, a CXCR4 antagonist, in CP/CPPS was evaluated in a murine model of experimental autoimmune prostatitis (EAP). The progression of EAP and T helper 17 (Th17) cell-mediated immune responses following AMD3100 intervention was assessed via HE staining

SUBMITTER: Hu Y 

PROVIDER: S-EPMC12905642 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature